Critical appraisal of trastuzumab in treatment of advanced stomach cancer
Judith Meza-Junco, Heather-Jane Au, Michael B SawyerDepartment of Oncology, Cross Cancer Institute, Edmonton, Alberta, CanadaAbstract: Advanced or metastatic gastric cancer constitutes the majority of patients in clinical practice. In North America, about 70% of cases are advanced or metastatic when...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-03-01
|
| Series: | Cancer Management and Research |
| Online Access: | http://www.dovepress.com/critical-appraisal-of-trastuzumab-in-treatment-of-advanced-stomach-can-a6545 |
| _version_ | 1818117185398112256 |
|---|---|
| author | Judith Meza-Junco Heather-Jane Au Michael B Sawyer |
| author_facet | Judith Meza-Junco Heather-Jane Au Michael B Sawyer |
| author_sort | Judith Meza-Junco |
| collection | DOAJ |
| description | Judith Meza-Junco, Heather-Jane Au, Michael B SawyerDepartment of Oncology, Cross Cancer Institute, Edmonton, Alberta, CanadaAbstract: Advanced or metastatic gastric cancer constitutes the majority of patients in clinical practice. In North America, about 70% of cases are advanced or metastatic when diagnosed, which is higher than the 50% reported in Japan. This difference in presentation is reflected in 5-year overall survival, which is about 20% in North America and 40%–60% in Japan. Despite numerous efforts of randomized studies on advanced gastric cancer, no globally accepted standard regimen has yet been established. Systemic chemotherapy provides palliation and prolongs survival, but the prognosis remains poor. Several monotherapies and combined regimens are currently available and vary around the world. Additionally, several molecular targeting agents are under evaluation in international randomized studies. Human epidermal growth factor receptor-2 (HER-2) is overexpressed or amplified in approximately 22% of patients with gastric cancer. Trastuzumab, a recombinant humanized anti-HER-2 monoclonal antibody, is the first biological therapy that has showed a survival improvement by nearly three months (reduced risk of death by 26%). Therefore, trastuzumab in combination with cisplatin is a reasonable treatment option for patients with advanced gastric cancer who are HER-2 positive. This paper will focus on trastuzumab, its chemical and pharmacological characteristics, and the relevant efficacy, safety, and tolerability studies.Keywords: gastric cancer, HER-2, trastuzumab |
| first_indexed | 2024-12-11T04:34:23Z |
| format | Article |
| id | doaj.art-5c1bc9a1b3704de8ae1693bf8c072757 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-11T04:34:23Z |
| publishDate | 2011-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-5c1bc9a1b3704de8ae1693bf8c0727572022-12-22T01:20:47ZengDove Medical PressCancer Management and Research1179-13222011-03-012011default5764Critical appraisal of trastuzumab in treatment of advanced stomach cancerJudith Meza-JuncoHeather-Jane AuMichael B SawyerJudith Meza-Junco, Heather-Jane Au, Michael B SawyerDepartment of Oncology, Cross Cancer Institute, Edmonton, Alberta, CanadaAbstract: Advanced or metastatic gastric cancer constitutes the majority of patients in clinical practice. In North America, about 70% of cases are advanced or metastatic when diagnosed, which is higher than the 50% reported in Japan. This difference in presentation is reflected in 5-year overall survival, which is about 20% in North America and 40%–60% in Japan. Despite numerous efforts of randomized studies on advanced gastric cancer, no globally accepted standard regimen has yet been established. Systemic chemotherapy provides palliation and prolongs survival, but the prognosis remains poor. Several monotherapies and combined regimens are currently available and vary around the world. Additionally, several molecular targeting agents are under evaluation in international randomized studies. Human epidermal growth factor receptor-2 (HER-2) is overexpressed or amplified in approximately 22% of patients with gastric cancer. Trastuzumab, a recombinant humanized anti-HER-2 monoclonal antibody, is the first biological therapy that has showed a survival improvement by nearly three months (reduced risk of death by 26%). Therefore, trastuzumab in combination with cisplatin is a reasonable treatment option for patients with advanced gastric cancer who are HER-2 positive. This paper will focus on trastuzumab, its chemical and pharmacological characteristics, and the relevant efficacy, safety, and tolerability studies.Keywords: gastric cancer, HER-2, trastuzumabhttp://www.dovepress.com/critical-appraisal-of-trastuzumab-in-treatment-of-advanced-stomach-can-a6545 |
| spellingShingle | Judith Meza-Junco Heather-Jane Au Michael B Sawyer Critical appraisal of trastuzumab in treatment of advanced stomach cancer Cancer Management and Research |
| title | Critical appraisal of trastuzumab in treatment of advanced stomach cancer |
| title_full | Critical appraisal of trastuzumab in treatment of advanced stomach cancer |
| title_fullStr | Critical appraisal of trastuzumab in treatment of advanced stomach cancer |
| title_full_unstemmed | Critical appraisal of trastuzumab in treatment of advanced stomach cancer |
| title_short | Critical appraisal of trastuzumab in treatment of advanced stomach cancer |
| title_sort | critical appraisal of trastuzumab in treatment of advanced stomach cancer |
| url | http://www.dovepress.com/critical-appraisal-of-trastuzumab-in-treatment-of-advanced-stomach-can-a6545 |
| work_keys_str_mv | AT judithmezajunco criticalappraisaloftrastuzumabintreatmentofadvancedstomachcancer AT heatherjaneau criticalappraisaloftrastuzumabintreatmentofadvancedstomachcancer AT michaelbsawyer criticalappraisaloftrastuzumabintreatmentofadvancedstomachcancer |